The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: A 2015 update

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 2, 2016, Pages 243-253

  Sutti, Salvatore ^a   Bruzzì, Stefania ^a   Albano, Emanuele ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Alcoholic liver disease (ALD); lipid peroxidation; liver fibrosis; natural killer T cells; nonalcoholic fatty liver diseases (NAFLD); oxidative stress; T lymphocytes

Indexed keywords

AUTOANTIBODY; CYTOKINE; ANTIBODY; AUTACOID;

ADAPTIVE IMMUNITY; ALCOHOLIC FATTY LIVER; AUTOIMMUNITY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY CELL; INNATE IMMUNITY; LIVER FIBROSIS; LIVER INJURY; LYMPHOCYTE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; REVIEW; ANIMAL; BLOOD; IMMUNOLOGY; IMMUNOTHERAPY; LIVER; LIVER DISEASES, ALCOHOLIC; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; LIVER; LIVER DISEASES, ALCOHOLIC; LYMPHOCYTES; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS;

EID: 84956834596     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1111758     Document Type: Review

References (88)

1. Papers of special note have been highlighted as
2. ∗ Of interest
3. ∗ Of considerable interest
4. Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol. 2015; 62 (1 Suppl): S38-S46
5. Tzukamoto H. Conceptual importance of identifying alcoholic liver disease as a lifestyle disease. J Gastroenterol. 2007; 42: 603-609
6. Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015; 35: 221-235
7. Rafiq N, Bai C, Fang Y., et al. Long-Term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009; 7: 234-238
8. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43: S99-S112
9. Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol. 2006; 23: 149-160
10. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology. 2014; 147: 754-764
11. Wong RJ, Aguilar M, Cheung R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148: 547-555
12. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013; 59: 160-168
13. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-Alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012; 56: 1384-1391
14. Stickel F. Alcoholic cirrhosis and hepatocellular carcinoma. Adv Exp Med Biol. 2015; 815: 113-130
15. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141: 1572-1585
16. Wang HJ, Gao B, Zakhari S., et al. Inflammation in alcoholic liver disease. Ann Rev Nutr. 2012; 32: 343-368
17. Rosso N, Chavez-Tapia NC, Tiribelli C., et al. Translational approaches: from fatty liver to non-Alcoholic steatohepatitis. World J Gastroenterol. 2014; 20: 9038-9049
18. Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015; 39: 763-775
19. Bieghs V, Trautwein C. Innate immune signaling and gut-liver interactions in nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2014; 3: 377-385
20. Petrasek J, Csak T, Ganz M., et al. Differences in innate immune signaling between alcoholic and non-Alcoholic steatohepatitis. J Gastroenterol Hepatol. 2012; 28 (Suppl 1): 82-93
21. Mehal WZ. The inflammasome in liver injury and non-Alcoholic fatty liver disease. Dig Dis. 2014; 32: 507-515
22. Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015; 12: 387-400
23. Albano E. Oxidative stress in alcoholic liver disease. In: Albano E, Parola M., editors. Oxidative stress in applied basic research and clinical practice: studies on hepatic disorders. Basel: Humana Press, Springer International Publishing; 2015. p. 215-239
24. Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2011; 15: 1325-1365
25. Miller YI, Choi SH, Weisner P., et al. Oxidation-specific epitopes are danger-Associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011; 108: 235-248
26. Weismann D, Binder CJ. The innate immune response to products of phospholipid peroxidation. Biochim Biophys Acta. 2012; 1818: 2465-2475
27. Albano E. Role of adaptive immunity in alcoholic liver disease. Int J Hepatol. 2012; 2012: 893026. DOI: 10.1155/2012/893026
28. Lemmers A, Moreno C, Gustot T., et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology. 2009; 49: 646-657
29. Klassen LW, Tuma D, Sorrell MF. Immune mechanisms of alcohol-induced liver disease. Hepatology. 1995; 22: 355-357
30. Vidali M, Stewart SF, Albano E. Interplay between oxidative stress and immunity in the progression of alcohol-mediated liver injury. Trends Mol Med. 2008; 14: 63-71
31. Sutti S, Rigamonti C, Vidali M., et al. CYP2E1 autoantibodies in liver diseases. Redox Biol. 2014; 3: 72-78
32. Gadd VL, Skoien R, Powell EE., et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014; 59: 1393-1405
33. Sutti S, Jindal A, Locatelli I., et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology. 2014; 59: 886-897
34. Weston CJ, Shepherd EL, Claridge LC. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest. 2015; 125: 501-520
35. Wolf MJ, Adili A, Piotrowitz K., et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-Talk with hepatocytes. Cancer Cell. 2014; 26: 549-564
36. Inzaugarat ME, Ferreyra Solari NE., et al. Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. J Clin Immunol. 2011; 31: 1120-1130
37. Ferreyra Solari NE, Inzaugarat ME., et al. The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. J Clin Immunol. 2012; 32: 611-621
38. Tang Y, Bian Z, Zhao L., et al. Inteleukin-17 exacerbates hepatic steatosis and inflammation in non-Alcoholic fatty liver disease. Clin Exp Immunol. 2011; 166: 281-290
39. Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012; 8: 709-716
40. Leibundgut G, Witztum JL, Tsimikas S. Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol. 2013; 13: 168-179
41. Stewart SF, Vidali M, Day CP., et al. Oxidative stress as a trigger for cellular immune response in patients with alcoholic liver disease. Hepatology. 2004; 39: 197-203
42. Thiele GM, Klassen LW, Tuma DJ. Formation and immunological properties of aldehyde-derived protein adducts following alcohol consumption. Methods Mol Biol. 2008; 447: 235-257
43. Thiele GM, Duryee MJ, Willis MS., et al. Autoimmune hepatitis induced by syngeneic liver cytosolic proteins biotransformed by alcohol metabolites. Alcohol Clin Exp Res. 2010; 34: 2126-2136
44. Albano E, Mottaran E, Vidali M., et al. Immune response toward lipid peroxidation products as a predictor of the progression of non-Alcoholic fatty liver disease (NAFLD) to advanced fibrosis. Gut. 2005; 54: 987-993
45. Nobili V, Parola M, Alisi A., et al. Oxidative stress parameters in paediatric non-Alcoholic fatty liver disease. Int J Mol Med. 2010; 26: 471-476
46. Anderson DR, Duryee MJ, Shurmur SW., et al. Unique antibody responses to malondialdehyde-Acetaldehyde (MAA)-protein adducts predict coronary artery disease. PLoS One. 2012; 9: e107440. DOI: 10.1371/journal.pone.01074402014
47. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62 (1 Suppl): S47-S64
48. Baumgardner JN, Shankar S, Hennings L., et al. N-Acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr. 2008; 138: 1872-1879
49. Chalasani N, Younossi Z, Lavine JE., et al. The diagnosis and management of non-Alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142: 1592-1609
50. Vidali M, Hietala J, Occhino G., et al. Immune responses against oxidative stress-derived antigens are associated with increased circulating tumor necrosis factor-α and accelerated liver damage in heavy drinkers. Free Rad Biol Med. 2008; 45: 306-311
51. Lou XY, Takara T, Kawai K., et al. IFN-γ deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine-And choline-deficient high fat diet. Am J Physiol Gastroinstest Liver Physiol. 2013; 305: G891-G899
52. Shimazu Y, Hamaguchi M, Fukuda T., et al. Steatohepatitis as impaired immune metabolism induced by liver resident regulatory T-cell depletion. Hepatology. 2015. DOI: 10.1002/hep.27986
53. Crispe IN. Immune tolerance in liver disease. Hepatology. 2014; 60: 2109-2117
54. Rensen SS, Slaats Y, Driessen A., et al. Activation of complement system in human non-Alcoholic fatty liver disease. Hepatology. 2009; 50: 1809-1817
55. Bieghs V, van Gorp PJ, Walenbergh SM., et al. Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology. 2012; 56: 894-903
56. Tsiantoulas D, Diehl CJ, Witztum JL., et al. B cells and humoral immunity in atherosclerosis. Circ Res. 2014; 114: 1743-1756
57. Wang H, Yin S. Natural killer T cells in liver injury, inflammation and cancer. Expert Rev Gastroenterol Hepatol. 2015; 9: 1077-1085
58. Kremer M, Thomas E, Milton RJ., et al. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology. 2010; 51: 130-141
59. Tang ZH, Liang S, Potter J., et al. Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol. 2013; 190: 1788-1796
60. Tajiri K, Shimizu Y, Tsuneyama K., et al. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009; 21: 673-680
61. Syn WK, Agboola KM, Swiderska M., et al. NKT-Associated hedgehog and osteopontin drive fibrogenesis in non-Alcoholic fatty liver disease. Gut. 2012; 61: 1323-1329
62. Maricic I, Sheng H, Marrero I., et al. Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Hepatology. 2015; 61: 1357-1369
63. Cui K, Yan G, Xu C., et al.,. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice. J Hepatol. 2015; 62: 1311-1318
64. Locatelli I, Sutti S, Vacchiano M., et al. NF-kB1 deficiency stimulates the progression of nonalcoholic steatohepatitis (NASH) in mice by promoting NKT-mediated responses. Clin Sci (Lond). 2013; 124: 279-287
65. Wehr A, Baeck C, Heymann F., et al. Chemokine receptor CXCR6-dependent hepatic NK T cell accumulation promotes inflammation and liver fibrosis. J Immunol. 2013; 190: 5226-5236
66. Gordy LE, Bezbradica JS, Flyak AI., et al. IL-15 regulates homeostasis and terminal maturation of NKT cells. J Immunol. 2011; 187: 6335-6345
67. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013; 14: 996-1006
68. Schildberg FA, Sharpe AH, Turley SJ. Hepatic immune regulation by stromal cells. Curr Opinion Immunol. 2015; 32: 1-6
69. Heymann F, Peusquens J, Ludwig-Portugall I., et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015; 62: 279-291
70. Ma X, Hua J, Mohamood AR., et al. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology. 2007; 46: 1519-1529
71. Tselios K, Sarantopoulos A, Gkougkourelas I., et al. T regulatory cells: a promising new target in atherosclerosis. Crit Rev Immunol. 2014; 34: 389-397
72. Eckert C, Klein N, Kornek M., et al. The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation. Front Immunol. 2015; 20: 179. DOI: 10.3389/fimmu.2015.00179
73. Rahman AH, Aloman C. Dendritic cells and liver fibrosis. Biochim Biophys Acta. 2013; 1832: 998-1004
74. Ibrahim J, Nguyen AH, Rehman A., et al. Dendritic cell populations with different concentrations of lipids regulates tolerance and immunity in mouse and human liver. Gastroentrology. 2012; 143: 1061-1072
75. Henning JR, Graffeo CS, Rehman A., et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology. 2013; 58: 589-602
76. Sutti S, Locatelli I, Bruzzì S., et al. CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis. Clin Sci (Lond). 2015; 129: 797-808
77. Domininguez PM, Ardavin C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol Rev. 2010; 234: 90-104
78. Seijkens T, Kusters P, Chatzigeorgiou A., et al. Immune cell crosstalk in obesity: a key role for costimulation? Diabetes. 2014; 63: 3982-3991
79. Chatzigeorgiou A, Chung KJ, Garcia-Martin R., et al. Dual role of B7 costimulation in obesity-related nonalcoholic steatohepatitis and metabolic dysregulation. Hepatology. 2014; 60: 1196-1210
80. Weiner HL, Pies da Cunha A, Quintana F., et al. Oral tolerance. Immunol Rev. 2011; 241: 241-259
81. Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells. Arterioscler Thromb Vasc Biol. 2015; 35: 280-287
82. Ilan Y, Maron R, Tukpah AM., et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A. 2010; 107: 9765-9770
83. Ilan Y, Zigmond E, Lalazar G., et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol. 2010; 30: 167-177
84. Lalazar G, Mizrahi M, Turgeman I., et al. Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo-controlled trial. J Clin Immunol. 2015; 35: 399-407
85. Mizrahi M, Shabat Y, Ben Yaacov A., et al. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res. 2012; 5: 141-150
86. Adar T, Ben Yaacov A, Lalazar G., et al. Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol. 2012; 167: 252-260
87. Kim KS, Surh CD. Induction of immune tolerance to dietary antigens. Adv Exp Med Biol. 2015; 850: 93-118
88. Elinav E, Pappo O, Sklair-Levy M., et al. Amelioration of non-Alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. J Pathol. 2006; 208: 74-81